Detalhe da pesquisa
1.
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.
N Engl J Med
; 381(17): 1621-1631, 2019 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31479209
2.
Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial.
Catheter Cardiovasc Interv
; 99(3): 676-685, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34233065
3.
Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data.
Circulation
; 142(6): 546-555, 2020 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32654539
4.
Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI-the POPular Risk Score study.
Eur J Clin Pharmacol
; 75(9): 1201-1210, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31197411
5.
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).
Am Heart J
; 198: 152-159, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29653637
6.
A clinical risk score to identify patients at high risk of very late stent thrombosis.
J Interv Cardiol
; 31(2): 159-169, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29468725
7.
How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).
Semin Thromb Hemost
; 43(4): 439-446, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28561235
8.
Incidence and Causes for Early Ticagrelor Discontinuation: A "Real-World" Dutch Registry Experience.
Cardiology
; 138(3): 164-168, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28697492
9.
Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
Am Heart J
; 170(5): 981-985.e1, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26542508
10.
CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
Am Heart J
; 168(1): 16-22.e1, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24952855
11.
Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.
J Thromb Thrombolysis
; 38(2): 127-36, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24043374
12.
Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study.
Front Pharmacol
; 13: 1032995, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545312
13.
Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial.
Am J Cardiovasc Drugs
; 22(2): 195-206, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34490590
14.
Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
Int J Cardiol
; 334: 10-17, 2021 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33887342
15.
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.
Circ Cardiovasc Interv
; 14(4): e009434, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33722066
16.
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
JACC Cardiovasc Interv
; 13(5): 606-617, 2020 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32139218
17.
Effect of CYP3A4*22 and PPAR-α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention.
Genes (Basel)
; 11(9)2020 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32932966
18.
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.
Clin Pharmacol Ther
; 108(5): 1067-1077, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32472697
19.
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Eur Heart J Cardiovasc Pharmacother
; 6(4): 203-210, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31504375
20.
Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment.
TH Open
; 2(4): e357-e368, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31249961